Dr. Reddy's Laboratories Limited reports news on its global pharmaceutical business, including APIs, generics, branded generics, biosimilars and OTC medicines. Company updates cover product approvals and launches in regulated markets, such as generic semaglutide in Canada and OTC ophthalmic products in the U.S., as well as biosimilar development, regulatory submissions and strategic partnerships.
Recurring coverage also includes IFRS financial results, segment trends across Global Generics and Pharmaceutical Services and Active Ingredients, and market activity in the USA, India, Russia and CIS countries, China, Brazil and Europe. Related research releases include Aurigene Oncology updates on oncology programs and targeted protein degradation platforms.
Dr. Reddy's Laboratories has launched a generic version of Sapropterin Dihydrochloride Tablets for oral use, marking a significant expansion in their product portfolio. Available in 100 mg dosage and bottle sizes of 120, this launch aims to provide affordable medications for patients, particularly for those affected by a rare disease. The company also offers a co-pay card program to assist eligible patients financially. This move underscores Dr. Reddy's commitment to enhancing healthcare accessibility while broadening their therapeutic offerings.
Dr. Reddy’s Laboratories has launched Cinacalcet Tablets, a generic version of Sensipar, approved by the USFDA. This therapeutic equivalent is expected to capture a share of the Sensipar market, which reported U.S. sales of about $312 million in the last twelve months ending July 2020. The tablets are available in 30 mg, 60 mg, and 90 mg dosages, packaged in bottles of 30. This launch aims to provide affordable treatment options and enhance Dr. Reddy's competitive product portfolio in the pharmaceutical market.
Dr. Reddy's Laboratories has launched Dimethyl Fumarate Delayed-Release Capsules, a generic equivalent of Tecfidera®, approved by the U.S. FDA. The launch addresses a significant market, with U.S. sales of the Tecfidera® brand reaching approximately $3.8 billion for the twelve months ending June 2020, according to IQVIA Health. The new capsules are available in 120 mg and 240 mg strengths, offered in bottles of 14 and 60 capsules. This development expands Dr. Reddy's generics portfolio aimed at providing affordable medicines.